Latest Breaking News On - Christian angermayer presight - Page 1 : comparemela.com

Chemomab Completes Merger with Anchiano Therapeutics USA - English Combined company will focus on advancing Chemomab s CM-101 currently in Phase 2 for rare fibrotic indications Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayer s Presight Capital and Apeiron Investment Group News provided by Share this article Share this article TEL-AVIV, Israel, March. 16, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the completion of its merger with Anchiano Therapeutics Ltd. ( Anchiano ).

Christian angermayer presightIrina kofflerNissim darvishJoel marylesSharon elkobiClaude nicaiseNeil cohenPeter thielGoldfarb seligmanBalan mosesStephen squintoWadi morNovo nordiskPrnewswire chemomab ltdApeiron investment groupLifesci advisors